1c:{"metadata":[["$","title","0",{"children":"NIH VideoCast - Anita Roberts Lecture - Advancing the Development of Effective Therapies for Children and Adults with Rare Tumors"}],["$","meta","1",{"name":"description","content":"Anita Roberts Lecture 2022\n

\nThe “Distinguished Women Scientists at NIH” lecture series highlights the outstanding research achievements of woman scientists in the NIH Intramural Research Program. This seminar is dedicated to Dr. Anita Roberts and honors her role as an exceptional mentor and scientist. \n

\nDr. Widemann is the Chief of the Pediatric Oncology Branch at NCI where she oversees basic, translational, and clinical research programs for children and young adults with hematologic and solid malignancies. Her research has been focused on drug development and early clinical trials for children with refractory solid tumors or genetic tumor predisposition syndromes, in particular neurofibromatosis type 1 (NF1). Her findings resulted in the first approved medical therapy for children with NF1."}],["$","meta","2",{"name":"publisher","content":"National Institutes of Health"}],["$","meta","3",{"property":"og:title","content":"NIH VideoCast - Anita Roberts Lecture - Advancing the Development of Effective Therapies for Children and Adults with Rare Tumors"}],["$","meta","4",{"property":"og:description","content":"Anita Roberts Lecture 2022\n

\nThe “Distinguished Women Scientists at NIH” lecture series highlights the outstanding research achievements of woman scientists in the NIH Intramural Research Program. This seminar is dedicated to Dr. Anita Roberts and honors her role as an exceptional mentor and scientist. \n

\nDr. Widemann is the Chief of the Pediatric Oncology Branch at NCI where she oversees basic, translational, and clinical research programs for children and young adults with hematologic and solid malignancies. Her research has been focused on drug development and early clinical trials for children with refractory solid tumors or genetic tumor predisposition syndromes, in particular neurofibromatosis type 1 (NF1). Her findings resulted in the first approved medical therapy for children with NF1."}],["$","meta","5",{"property":"og:url","content":"https://uat.d1rkikwu4q8tg.amplifyapp.com/watch/c7da3eee-d5db-11f0-9cf9-12c45c580ad9"}],["$","meta","6",{"property":"og:site_name","content":"NIH VideoCast"}],["$","meta","7",{"property":"og:image","content":"https://nihcit.rev.vbrick.com/api/v2/media/videos/thumbnails/02e1505d-ed46-4bbb-80f5-ed85eaf162c5.jpg"}],["$","meta","8",{"property":"og:type","content":"website"}],["$","meta","9",{"name":"twitter:card","content":"summary_large_image"}],["$","meta","10",{"name":"twitter:title","content":"NIH VideoCast - Anita Roberts Lecture - Advancing the Development of Effective Therapies for Children and Adults with Rare Tumors"}],["$","meta","11",{"name":"twitter:description","content":"Anita Roberts Lecture 2022\n

\nThe “Distinguished Women Scientists at NIH” lecture series highlights the outstanding research achievements of woman scientists in the NIH Intramural Research Program. This seminar is dedicated to Dr. Anita Roberts and honors her role as an exceptional mentor and scientist. \n

\nDr. Widemann is the Chief of the Pediatric Oncology Branch at NCI where she oversees basic, translational, and clinical research programs for children and young adults with hematologic and solid malignancies. Her research has been focused on drug development and early clinical trials for children with refractory solid tumors or genetic tumor predisposition syndromes, in particular neurofibromatosis type 1 (NF1). Her findings resulted in the first approved medical therapy for children with NF1."}],"$L22","$L23","$L24"],"error":null,"digest":"$undefined"}